Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

Inclusion Criteria:

* Signed, informed consent
* Histologically confirmed, locally-advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) or other malignancies known to express CA19-9 positive malignancies
* At least one lesion by CT or MRI ≥ 2 cm
* ECOG performance status of 0 to 2
* Absolute neutrophil count ≥1.50 x 109/L
* Hemoglobin ≥ 9.0 g/dL (in the absence of red blood cell transfusions in the prior 14 days)
* Platelet count \>75,000/ mm3
* AST/SGOT, ALT/SGPT ≤2.5 x ULN, unless liver metastases are clearly present, then ≤5.0 x ULN
* Total bilirubin \<1.5x the upper limit of normal unless considered due to Gilbert's syndrome in which case, \<3x the upper limit of normal
* Serum creatinine (serum or plasma) ≤ 1.5 x ULN or GFR\>50 mL/min
* Serum albumin \> 3.0g/dL
* Willingness to participate in collection of pharmacokinetic samples
* Willingness to use adequate contraception throughout study and for a period of 90 days last dose of study drug

Exclusion Criteria:

* Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
* Major surgery other than diagnostic surgery within 28 days
* History of anaphylactic reaction to human, or humanized, antibody
* Other on-going cancer therapy or investigational agents (except MVT-5873 )
* Known history of HIV or Hepatitis C
* Pregnant or currently breast-feeding
* Psychiatric illness/social situations that would interfere with compliance with study requirements
* Significant cardiovascular risk including, but not limited to, recent (within 28 days) coronary stenting or myocardial infarction within 6 months